Criteria for Surrogate End Points
From MaRDI portal
Publication:5088204
DOI10.1111/J.1467-9868.2007.00617.XOpenAlexW2122194038MaRDI QIDQ5088204FDOQ5088204
Authors: Hua Chen, Zhi Geng, Jinzhu Jia
Publication date: 11 July 2022
Published in: Journal of the Royal Statistical Society Series B: Statistical Methodology (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1111/j.1467-9868.2007.00617.x
Cited In (4)
- Linear increment in efficiency with the inclusion of surrogate endpoint
- Semiparametric pseudo-score and pseudo-likelihood for evaluating correlate of protection in vaccine trials
- Evaluating Candidate Principal Surrogate Endpoints
- Estimation of the proportion of treatment effect explained by a high-dimensional surrogate
This page was built for publication: Criteria for Surrogate End Points
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5088204)